A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center

Haemophilia

Volumn 18, Issue 4, 2012, Pages 561-567

  Dodd, C ^a   Watts, R G ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Central venous catheter; Haemophilia; Hemarthrosis; Outcome; Primary prophylaxis; Secondary prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR;

ADOLESCENT; ARTICLE; BLEEDING; CANADA; CHILD; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG TREATMENT FAILURE; ELECTRONIC MEDICAL RECORD; FOLLOW UP; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; INFANT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIMARY PREVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SECONDARY PREVENTION; TREATMENT DURATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COAGULANTS; DRUG ADMINISTRATION SCHEDULE; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 84863192453     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02741.x     Document Type: Article

References (13)

1. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32. PMID:1640190.
2. Manco-Johnson MJ, Abshire TC, Evatt BL et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophilia. N Engl J Med 2007; 357: 535-44. PMID:17687129.
3. Blanchette VS. Prophylaxis in the haemophilia population. Haemophilia 2010; 16 Suppl. 5: 181-8. PMID:20590879.
4. Feldman BM, Pai M, Blanchette VS et al. Tailored prophylaxis in severe haemophilia A: interim results from the first 5years of the Canadian Haemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-36. PMID:16706965.
5. Risebrough N, Oh P, Feldman BM, et al. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Haemophilia 2008; 14: 743-52. PMID:18422610.
6. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965 (Suppl. 77): 3-132.
7. Lofqvist T, Nilsson IM, Berntorp D, Pettersson H. Haemophilia prophylaxis in young patients-a long term followup. J Intern Med 1997; 241: 395-400.
8. Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R. Optimizing factor prophylaxis for the haemophilia population: where do we stand?Haemophilia 2004; 10(Suppl. 4): 97-104.
9. Colton T. Statistics in Medicine. Boston: Little, Brown and Company, 1974.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
11. Swinscow TDV. Statistics at Square One. London: British Medical Association and British Medical Journal, 1983.
12. United States Centers for Disease Control and Prevention. Universal Data System Data Reports (National report, Treatment/clinical characteristics (Haemophilia)). Retrieved from the Web June 23, 2011.
13. Fischer K, Astermark J, van der Born JG et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8: 753-60.